At a glance
Infectious diseases
COGS as low as ~€1 per dose on a 20-million-dose mRNA campaign
10 million 50µg doses — or 50 million 10µg doses — in 100 days
One architecture serves routine R&D and pandemic surge, with no tech transfer or re-validation in between
Regional manufacturers own their vaccine portfolios
Faster deployment, lower cost, and vaccine autonomy
Vaccine autonomy shouldn't depend on someone else's factory. Our platform lets a regional hub run endemic volumes today and flip, on the same line, with no re-validation, into pandemic-surge capacity tomorrow.
One process. One partner. National autonomy, at the push of a button.
Rabies (preclinical, mouse model)
A full proof-of-concept RNA vaccine, designed and produced end-to-end on N-Force, reached protection above the WHO correlate of protection — on par with reference lipid formulations, but with full freedom-to-operate.
Read the rabies case study →